Natixis Acquires Shares of 60,500 AtriCure, Inc. (NASDAQ:ATRC)

Natixis purchased a new position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 60,500 shares of the medical device company's stock, valued at approximately $1,849,000. Natixis owned approximately 0.12% of AtriCure as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in ATRC. Geode Capital Management LLC grew its stake in shares of AtriCure by 2.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,152,628 shares of the medical device company's stock worth $32,326,000 after buying an additional 32,676 shares in the last quarter. Silver Oak Securities Incorporated bought a new position in shares of AtriCure during the fourth quarter valued at approximately $220,000. JPMorgan Chase & Co. raised its holdings in shares of AtriCure by 43.1% in the fourth quarter. JPMorgan Chase & Co. now owns 365,183 shares of the medical device company's stock worth $11,160,000 after buying an additional 110,039 shares during the period. Calamos Advisors LLC lifted its stake in shares of AtriCure by 27.9% during the 4th quarter. Calamos Advisors LLC now owns 110,671 shares of the medical device company's stock worth $3,382,000 after acquiring an additional 24,147 shares during the last quarter. Finally, M&T Bank Corp purchased a new position in AtriCure during the 4th quarter valued at $208,000. Institutional investors own 99.11% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently commented on ATRC. JPMorgan Chase & Co. reduced their price target on shares of AtriCure from $51.00 to $46.00 and set an "overweight" rating on the stock in a research note on Thursday, March 27th. Canaccord Genuity Group reduced their price objective on shares of AtriCure from $66.00 to $52.00 and set a "buy" rating for the company in a research note on Friday, March 28th. BTIG Research reaffirmed a "buy" rating on shares of AtriCure in a research report on Thursday, March 27th. Oppenheimer boosted their price target on AtriCure from $36.00 to $45.00 and gave the stock an "outperform" rating in a research report on Thursday, February 13th. Finally, Stifel Nicolaus upped their price objective on AtriCure from $36.00 to $48.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $49.44.

AtriCure Stock Performance

Shares of NASDAQ ATRC traded up $0.49 during mid-day trading on Monday, hitting $33.89. The stock had a trading volume of 104,756 shares, compared to its average volume of 574,223. The company has a 50 day moving average of $34.32 and a two-hundred day moving average of $34.66. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.62 and a current ratio of 3.65. The firm has a market cap of $1.68 billion, a PE ratio of -35.85 and a beta of 1.65. AtriCure, Inc. has a twelve month low of $18.94 and a twelve month high of $43.11.

Insider Activity at AtriCure

In related news, Director Karen Prange sold 6,100 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the transaction, the director now directly owns 17,828 shares in the company, valued at $679,603.36. The trade was a 25.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.50% of the stock is owned by insiders.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.